These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23160853)

  • 1. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.
    Spitaleri G; Berardi R; Pierantoni C; De Pas T; Noberasco C; Libbra C; González-Iglesias R; Giovannoni L; Tasciotti A; Neri D; Menssen HD; de Braud F
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):447-55. PubMed ID: 23160853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
    Papadia F; Basso V; Patuzzo R; Maurichi A; Di Florio A; Zardi L; Ventura E; González-Iglesias R; Lovato V; Giovannoni L; Tasciotti A; Neri D; Santinami M; Menssen HD; De Cian F
    J Surg Oncol; 2013 Feb; 107(2):173-9. PubMed ID: 22674435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
    Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
    Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study.
    Van Limbergen EJ; Hoeben A; Lieverse RIY; Houben R; Overhof C; Postma A; Zindler J; Verhelst F; Dubois LJ; De Ruysscher D; Troost EGC; Lambin P
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1421-1430. PubMed ID: 33285270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
    Danielli R; Patuzzo R; Di Giacomo AM; Gallino G; Maurichi A; Di Florio A; Cutaia O; Lazzeri A; Fazio C; Miracco C; Giovannoni L; Elia G; Neri D; Maio M; Santinami M
    Cancer Immunol Immunother; 2015 Aug; 64(8):999-1009. PubMed ID: 25971540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.
    Gillessen S; Gnad-Vogt US; Gallerani E; Beck J; Sessa C; Omlin A; Mattiacci MR; Liedert B; Kramer D; Laurent J; Speiser DE; Stupp R
    Eur J Cancer; 2013 Jan; 49(1):35-44. PubMed ID: 22918078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.
    Johannsen M; Spitaleri G; Curigliano G; Roigas J; Weikert S; Kempkensteffen C; Roemer A; Kloeters C; Rogalla P; Pecher G; Miller K; Berndt A; Kosmehl H; Trachsel E; Kaspar M; Lovato V; González-Iglesias R; Giovannoni L; Menssen HD; Neri D; de Braud F
    Eur J Cancer; 2010 Nov; 46(16):2926-35. PubMed ID: 20797845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
    de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
    Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
    Giantonio BJ; Alpaugh RK; Schultz J; McAleer C; Newton DW; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson PO; Kalland T; Dohlsten M; Persson B; Weiner LM
    J Clin Oncol; 1997 May; 15(5):1994-2007. PubMed ID: 9164211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.
    Haense N; Atmaca A; Pauligk C; Steinmetz K; Marmé F; Haag GM; Rieger M; Ottmann OG; Ruf P; Lindhofer H; Al-Batran SE
    BMC Cancer; 2016 Jul; 16():420. PubMed ID: 27387446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
    Borghaei H; Alpaugh K; Hedlund G; Forsberg G; Langer C; Rogatko A; Hawkins R; Dueland S; Lassen U; Cohen RB
    J Clin Oncol; 2009 Sep; 27(25):4116-23. PubMed ID: 19636016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
    Hassan R; Cohen SJ; Phillips M; Pastan I; Sharon E; Kelly RJ; Schweizer C; Weil S; Laheru D
    Clin Cancer Res; 2010 Dec; 16(24):6132-8. PubMed ID: 21037025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
    Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
    Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
    Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.